Watch Live

Tweet TWEET

Pluristem Completes Large Scale Cell Therapy Formulation for Commercial and Clinical Trial Use

Pluristem Completes Large Scale Cell Therapy Formulation for Commercial and
Clinical Trial Use

Scaled-Up Process Enables the Production Potential of Billions of Live Cells
Simultaneously

HAIFA, Israel, Nov. 7, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today the Company has successfully completed the
integration and testing of its new scaled-up formulation and manufacturing
process to produce high-yield quantities of its Placental eXpanded (PLX) cells
for clinical trials and potential commercial use. The increased automation and
larger scale process allows the company to produce billions of live cells
simultaneously.

As part of its manufacturing process, Pluristem has optimized growth
conditions to maximize yields with lower costs. The company has minimized open
manipulation steps in order to improve the aseptic quality and safety of the
product. Critical steps have been automated including the process of
harvesting and purification; the integration of closed system washing and
concentration steps, and the product's final packaging has been changed to an
aseptically automated vial system. In the past 15 months, Pluristem has
invested resources and efforts to develop technologies resulting in an
efficient, cutting edge production line. All of the integrated changes have
been tested and will be integrated into Pluristem's new production site in
Israel.

Pluristem recently announced it is in the final steps of building out its new
manufacturing facility, which will have the capacity to produce commercial
grade PLX cells. Once completed, and following regulators' approval, the new
facility would have the capacity to produce PLX cells for the treatment of
over 150,000 patients annually estimated by Pluristem at $1 billion in
production value.

"This new large scale manufacturing process allows us to run numerous clinical
trials simultaneously around the globe, and also prepares us for potential
commercial availability," stated Zami Aberman, Chairman and CEO of Pluristem.
"Our progress with both our manufacturing process and facility are well on
track."

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the development of PLX cells administered locally to potentially treat
systemic diseases and potentially obviating the need to use the intravenous
route.

Data from two phase I studies indicate that Pluristem's first PLX product
candidate, PLX-PAD, is safe and potentially effective for the treatment of end
stage peripheral artery disease when given locally. Additionally, Pluristem is
developing PLX-PAD for cardiac ischemia; PLX-BMP for Acute Radiation Exposure,
Bone Marrow Transplant Failure and Chemotherapy induced Bone Marrow Aplasia,
PLX-ORTHO for orthopedic indications and PLX-PAH for Pulmonary Hypertension in
collaboration with United Therapeutics. Pluristem's pre-clinical animal models
have demonstrated PLX cells are also potentially effective in other
inflammatory/ischemic indications, including diastolic heart failure,
inflammatory bowel disease, neuropathic pain and pulmonary fibrosis.

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit www.pluristem.com and follow Pluristem on Twitter@Pluristem,
the content of which is not part of this press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss how the
increased automation and larger scale process allows us to produce billions of
live cells simultaneously, when we discuss the integration of changes into our
new production site, when we discuss our new manufacturing facility, its
planned capacity for production of PLX cells and estimated production value
assuming the PLX cells product candidates are successfully developed and
approved by the regulators, when we discuss that the new manufacturing process
allows us to run numerous clinical trials simultaneously around the globe, and
also prepares us for potential commercial availability, when we discuss that
PLX cells are safe and can potentially treat PAD or that PLX cells are also
potentially effective in other inflammatory/ischemic indications, we are using
forward-looking statements. These forward-looking statements are based on the
current expectations of the management of Pluristem only, and are subject to a
number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may
not be approved by regulatory agencies, our technology may not be validated as
we progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose knowledge
is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not translate to
equally good results in real surgical settings; results of preclinical studies
may not correlate with the results of human clinical trials; our patents may
not be sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.